Modified/Controlled Release of Liquid Oral Drugs
Flamel’s LiquiTime® platform uses Micropump®’s competitive advantages to allow us to develop modified/controlled release (e.g. near zero-order kinetics) in liquid suspension formulations.
This graph illustrates the different near zero-order release profiles which can be tailored for the same drug
The LiquiTime® products are particularly suitable for dosing to children and for use by patients having issues swallowing tablets or capsules. Unlike the other product examples described in the previous paragraph, which are all based on ion exchange resin technology, LiquiTime® does not have the limitation of having to work solely with ionic drugs and therefore has applicability to a much broader range of drug molecules.
As with Micropump®, LiquiTime® can be applied to the development of combination products and it is readily able to be scaled-up to commercial quantities.